These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24673985)

  • 41. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
    Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Parkinson's disease: from pallidotomy to L-dopa and back to pallidotomy].
    Pikielny RT
    Medicina (B Aires); 1997; 57(1):104-10. PubMed ID: 9435379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapies in Parkinson's disease.
    Jankovic J; Poewe W
    Curr Opin Neurol; 2012 Aug; 25(4):433-47. PubMed ID: 22691758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
    Rascol O
    Expert Opin Pharmacother; 2005 Oct; 6(12):2061-75. PubMed ID: 16197359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New pharmacologic horizons in the treatment of Parkinson disease.
    Bonuccelli U; Del Dotto P
    Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The current therapies for parkinson's disease. Part I: pharmacological treatment].
    Krygowska-Wajs A; Wszolek ZK; Uitti RJ; Słowinski J; Szczudlik A
    Neurol Neurochir Pol; 2003; 37(3):665-76. PubMed ID: 14593760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progress in neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients.
    Brusa L; Musco S; Bernardi G; Iani C; Pierantozzi M; Stanzione P; Stefani A; Finazzi Agro' E
    Parkinsonism Relat Disord; 2014 Aug; 20(8):931-2. PubMed ID: 24861661
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacological therapy of Parkinson's disease: current options and new avenues.
    Simola N; Pinna A; Fenu S
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rasagiline, sleep quality and well-being in Parkinson's disease: a pilot study.
    Mutti C; Sarnataro RB; Beretta J; Enzo P; Negrotti A; Rausa F; Pizzarotti S; Parrino L
    Neurol Sci; 2022 Aug; 43(8):4791-4796. PubMed ID: 35334012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.